ticagrelor + ASA — Competitive Intelligence Brief

ticagrelor + ASA (ticagrelor + ASA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent. Area: Cardiovascular.

marketed Dual antiplatelet agent P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin) Cardiovascular Small molecule

Target snapshot

ticagrelor + ASA (ticagrelor + ASA) — Peking University Third Hospital. Ticagrelor and aspirin work together to inhibit platelet aggregation through different pathways, reducing blood clot formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ticagrelor + ASA TARGET	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Aspirin + Ticagrelor	Aspirin + Ticagrelor	The First Affiliated Hospital with Nanjing Medical University	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (ticagrelor)
Aspirin combined with clopidogrel	Aspirin combined with clopidogrel	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Dual antiplatelet agent	Cyclooxygenase (COX) and P2Y12 receptor
Active Comparator: Aspirin+Clopidogrel	Active Comparator: Aspirin+Clopidogrel	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Aspirin and clopidogrel/Ticagrelor	Aspirin and clopidogrel/Ticagrelor	Beijing Neurosurgical Institute	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor)
Clopidogrel with aspirin	Clopidogrel with aspirin	University of Florida	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent class)

1. Seoul National University Hospital · 3 drugs in this class
2. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
3. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
4. Inova Health Care Services · 1 drug in this class
5. Peking University Third Hospital · 1 drug in this class
6. Rigshospitalet, Denmark · 1 drug in this class
7. Texas Cardiac Arrhythmia Research Foundation · 1 drug in this class
8. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
9. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
10. University of Athens · 1 drug in this class